Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy (LOWOL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04297423|
Recruitment Status : Not yet recruiting
First Posted : March 5, 2020
Last Update Posted : March 5, 2020
Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it.
Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: Plenvu||Phase 4|
The primary objective of the study is to compare the clinical efficacy (by comparing the adenoma detection rate) of 1L PEG plus ascorbate versus magnesium citrate plus picosulphate in subjects undergoing colonoscopy in a colorectal cancer screening programme. We also will compare the Lesion Detection Rate, the quality of colon cleansing (Boston classification) overall and by segments, the tolerability and satisfaction and the rate of adverse effects experienced with intake of these products.
Methodology: A comparative, parallel, randomized, single-centre, low-intervention clinical trial to be conducted at the CCR screening unit of Hospital Clínic de Barcelona that will include 1,002 participants.
Subjects will complete a Tolerability and Satisfaction Questionnaire after completing the bowel preparation. Findings (polyps, CRC, or other lesions) and quality of bowel cleansing will be collected from the colonoscopy report.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1002 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||A comparative, parallel, randomized, non-inferiority, non-blinded, single-centre and low-intervention clinical trial|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Eficacia y Tolerabilidad de Dos Productos de Volumen Reducido Para la Colonoscopia de Cribado: Ensayo Comparativo Paralelo Aleatorizado|
|Estimated Study Start Date :||March 17, 2020|
|Estimated Primary Completion Date :||March 1, 2021|
|Estimated Study Completion Date :||September 1, 2021|
Plenvu split dose
Other Name: citrafleet
Active Comparator: Citrafleet
citrafleet in split dose
Other Name: citrafleet
- Adenoma detection rate [ Time Frame: 1 year ]The percentage of patients with at least one adenoma in relation to the total subjects in each group of study
- Colonoscopy quality [ Time Frame: 1 year ]Colonoscopy quality is assess with Boston Bowel Preparation Scale (BBPS) in which each colon segment (right colon, transverse colon, and left colon) is scored from 0 to 3 (0=poor, 1=fair, 2=good, 3=excellent). It will be considered adequate when each segment is scored ≥2.
- Lesion detection rate [ Time Frame: 1 year ]The percentage of patients with at least one polyp in relation to the total subjects in each group
- Caecal intubation rate [ Time Frame: 1 year ]If the caecum has been reached in the colonoscopy, it will be considered complete; otherwise, it will be considered incomplete
- Rate of adverse events related to the administration of the preparation [ Time Frame: 1 year ]Evaluated with the Tolerability and Satisfaction Questionnaire including symptoms such as nausea, vomiting, abdominal pain, bloating, headache, chills, dizziness, and dry mouth
- Tolerability and satisfaction with preparation [ Time Frame: 1 year ]Assessed by completing a tolerability and satisfaction questionnaire that has been prepared from the validated questionnaire Mayo Clinic Bowel Prep Tolerability Questionnaire (Patel M, Staggs E, Thomas CS, Lukens F, Wallace M, Almansa C. Development and validation of the Mayo Clinic Bowel Prep Tolerability Questionnaire. Dig Liver Dis. 2014 Sep; 46(9):808-12.doi: 10.1016/j.dld.2014.05.020. Epub 2014 Jun 19. PubMed PMID: 24953203) and which has been adapted and translated into Spanish
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04297423
|Contact: María Pellisé, MD PhD||+34 932275400 ext email@example.com|